ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.344,88
0,30%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7346
-0,01%
Bitcoin
84.171,86
0,15%
Brent Oil
71,775
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Prothena Corporation PLC (PRTA)

  7. Prothena Corporation PLC (PRTA) Notícias

PRTA

Prothena (PRTA)

Prothena Corporation PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRTA
DataHoraFonteTítuloCódigoCompanhia
07/03/202518:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
27/02/202519:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRTAProthena Corporation PLC
20/02/202518:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
20/02/202518:05Business WireProthena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
14/02/202517:35Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PRTAProthena Corporation PLC
13/02/202518:05Business WireProthena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025NASDAQ:PRTAProthena Corporation PLC
03/01/202521:45Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:PRTAProthena Corporation PLC
30/12/202418:05Business WireProthena Announces Board of Directors UpdateNASDAQ:PRTAProthena Corporation PLC
19/12/202403:05Business WireRoche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s DiseaseNASDAQ:PRTAProthena Corporation PLC
13/11/202409:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PRTAProthena Corporation PLC
12/11/202418:05Business WireProthena Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
05/11/202418:05Business WireProthena to Report Third Quarter 2024 Financial Results on November 12NASDAQ:PRTAProthena Corporation PLC
03/10/202419:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
27/09/202417:05Business WireProthena Announces Leadership Team UpdatesNASDAQ:PRTAProthena Corporation PLC
29/08/202417:05Business WireProthena to Participate in Upcoming Healthcare ConferencesNASDAQ:PRTAProthena Corporation PLC
08/08/202418:13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRTAProthena Corporation PLC
08/08/202417:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTAProthena Corporation PLC
08/08/202417:05Business WireProthena Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/08/202417:05Business WireProthena to Report Second Quarter 2024 Financial Results on August 8NASDAQ:PRTAProthena Corporation PLC
28/05/202417:05Business WireProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationNASDAQ:PRTAProthena Corporation PLC
08/05/202417:05Business WireProthena Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/05/202417:05Business WireProthena to Report First Quarter 2024 Financial Results on May 8NASDAQ:PRTAProthena Corporation PLC
15/04/202417:05Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaNASDAQ:PRTAProthena Corporation PLC
04/03/202418:05Business WireProthena Appoints David Ford to Newly Created Chief People Officer PositionNASDAQ:PRTAProthena Corporation PLC
22/02/202419:29Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PRTAProthena Corporation PLC
21/02/202418:05Business WireProthena Announces Appointment of Daniel G. Welch as Director and Chair DesignateNASDAQ:PRTAProthena Corporation PLC
15/02/202418:05Business WireProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
14/02/202414:16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PRTAProthena Corporation PLC
13/02/202421:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRTAProthena Corporation PLC
08/02/202418:05Business WireProthena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024NASDAQ:PRTAProthena Corporation PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRTA

Seu Histórico Recente

TSX
CURA
Curaleaf
LSE
RSI
LSE
REE
Altona Rare Earths
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios